Difficulty: Medium
Average Score: 78%
Practice
A child is undergoing remission induction therapy to treat leukemia. Allopurinol is included in the regimen. The main reason for administering allopurinol as part of the clientÔÇÖs chemotherapy regimen is to:
Correct answer
A
Rationale
The correct answer is A) Prevent metabolic breakdown of xanthine to uric acid.
In pediatric oncology, especially during leukemia treatment, tumor lysis syndrome (TLS) is a potential complication due to the rapid breakdown of cancer cells leading to the release of intracellular contents like purines. Allopurinol is administered to inhibit xanthine oxidase, preventing the conversion of xanthine to uric acid, thus reducing the risk of uric acid crystal formation and subsequent renal damage.
Option B is incorrect because allopurinol is not directly involved in preventing uric acid from precipitating in the ureters but rather in inhibiting its formation.
Option C is incorrect as allopurinol does not enhance uric acid production but rather inhibits its formation.
Option D is incorrect as allopurinol's primary role in this scenario is related to preventing the metabolic breakdown of purines, not protecting the bone marrow from chemotherapy.
Understanding the rationale behind using allopurinol in the context of TLS risk during leukemia treatment is crucial for pediatric nurses to provide safe and effective care to their patients undergoing chemotherapy.
In pediatric oncology, especially during leukemia treatment, tumor lysis syndrome (TLS) is a potential complication due to the rapid breakdown of cancer cells leading to the release of intracellular contents like purines. Allopurinol is administered to inhibit xanthine oxidase, preventing the conversion of xanthine to uric acid, thus reducing the risk of uric acid crystal formation and subsequent renal damage.
Option B is incorrect because allopurinol is not directly involved in preventing uric acid from precipitating in the ureters but rather in inhibiting its formation.
Option C is incorrect as allopurinol does not enhance uric acid production but rather inhibits its formation.
Option D is incorrect as allopurinol's primary role in this scenario is related to preventing the metabolic breakdown of purines, not protecting the bone marrow from chemotherapy.
Understanding the rationale behind using allopurinol in the context of TLS risk during leukemia treatment is crucial for pediatric nurses to provide safe and effective care to their patients undergoing chemotherapy.